ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

TAVR (TAVI)

January 27, 2023
A novel self-expanding TAVR valve has been successfully implanted in ten patients, as reported by a research team in China. The new device is made of a self-expanding nitinol stent with three valve leaflets of bovine pericardial, reduces the risk of coronary obstruction, and is completely retrievable and repositionable.
January 12, 2023
INTEGRITTY, a group dedicated the appraisal of evidence to support optimized patient management, published a paper highlighting concerns surrounding major TAVR versus SAVR studies. While their findings do not aim to directly discredit the studies, they do raise questions about the integrity of their methodology.
December 21, 2022
A comparative study between five types of transcatheter heart valves found that although adverse outcome rates are low among all devices, some differences do stand out.
September 2, 2022
In the past, there has not been an accurate way to calculate mortality risk for patients with atrial fibrillation (AF) who have undergone a successful transcatheter aortic valve implantation (TAVI) and have been discharged home.
June 4, 2021
On May 25, 2021, Dr. David Heimansohn successfully performed the first surgical implantation of biopolymer Tria™ heart valve in a patient with mitral valve disease at Ascension St. Vincent Hospital, Indianapolis, IN. 
February 21, 2021
In this article, Thourani et al present the International Society for Minimally Invasive Cardiothoracic Surgery Expert Consensus Statement on transcatheter and surgical aortic valve replacement in low- and intermediate-risk patients: A meta-analysis of randomized and propensity-matched studies.
February 21, 2021
In this article, Kilcoyne et al discuss the current status of training cardiothoracic surgery trainees in structural heart disease and propose a new core curriculum for training surgeons in structural heart disease. 
June 11, 2020
As TAVR is used in progressively lower-risk cohorts, management of device failure will become increasingly important. This study reports the largest series of patients receiving a surgical reoperation after transcatheter aortic valve replacement (TAVR) using the STS Adult Cardiac Surgery Database.
February 26, 2020
Five year results of the PARTNER II trial demonstrated no difference in the risk of stroke or death comparing TAVR to surgical aortic valve replacement among intermediate surgical risk patients.  
November 22, 2019
Puzzling subgroup from the GALILEO trial, which appears in the same issue of the periodical as an article that discredits the use of rivaroxaban as thromboprevention strategy :

Pages